세계 피부과 의약품 시장 규모는 2030년까지 308억 8,013만 달러에 달할 것으로 예상되며, 2024-2030년 예측 기간 동안 연평균 10.62% 성장할 것으로 예상됩니다. 이 시장은 전 세계적으로 다양한 피부 질환의 부담이 증가함에 따라 큰 성장을 보이고 있습니다. 또한, 피부 건강에 대한 사람들의 인식 증가, 피부 관리 및 퍼스널케어에 대한 지출 증가, 피부 질환에 취약한 노인 환자의 부담 증가, 여드름 및 기타 사춘기 관련 피부 질환에 취약한 청소년 인구의 증가 등이 향후 몇 년 동안 시장을 견인할 것으로 예상됩니다. 따라서 시장은 2024-2030년 예측 기간 동안 상당한 CAGR로 성장할 것으로 예상됩니다.
피부과 의약품의 시장 역학
피부과 의약품 시장을 이끄는 중요한 측면 중 하나는 전 세계적으로 수많은 피부 질환의 부담이 증가하고 있다는 점입니다. 예를 들어, 여드름, 기미, 잔주름, 주름과 같은 피부 문제에 대한 관심 증가는 시장의 주요 성장 촉진요인입니다. 인구가 증가함에 따라 더 많은 사람들이 사춘기를 맞이하고 호르몬 및 신체 변화의 결과로 여드름, 여드름, 안면 홍조와 같은 특정 피부 문제에 직면하게 됩니다. 여드름은 일시적 또는 영구적인 흉터, 부정적인 자기 이미지, 불안을 유발하여 사람들 사이에서 다양한 피부과 약물을 고려하게 만듭니다.
또한, 피부 건강에 대한 대중의 인식이 높아지면서 피부과 의약품 시장 성장에 힘을 실어주고 있습니다. 유명인 문화, 소셜 미디어, 미인 대회, 영화, 미용 광고 등의 영향으로 여성들은 투명하고 건강하며 매력적인 피부를 원하고 있으며, 이러한 모든 요인들이 피부과 의약품 시장에 긍정적인 영향을 미치고 있습니다.
National Organization for Rare Disorders의 최신 조사에 따르면, 선천성 파키오니아(PC)라는 희귀 각화성 피부질환의 유병률은 2021년 전 세계적으로 5,000-1만 명에 달할 것으로 보고되고 있습니다. 따라서 이러한 피부 질환의 증가로 인해 관련 약품에 대한 수요가 증가할 것으로 예상됩니다.
또한 노령 인구의 증가도 피부과 의약품 시장의 성장 촉진요인 중 하나입니다. 세계보건기구(WHO)의 2021년 발표에 따르면 세계 인구의 고령화가 가속화되고 있으며, 2050년까지 세계 인구의 80%가 노인이 될 것이라고 합니다. 나이가 들어감에 따라 주름, 처짐, 기미, 잡티, 피부 트러블과 같은 피부 문제가 다른 사람보다 점차 발생하기 쉽습니다. 이에 따라 많은 사람들이 라파마이신과 같은 피부과 약물을 통한 노화 방지 치료를 선택하고 있으며, 전체 피부과 의약품 시장 점유율이 확대되고 있습니다.
주요 기업의 전략적 활동 증가, 제품 승인 및 출시 증가로 인해 시장에서 피부과 의약품에 대한 수요가 증가하고 있습니다. 예를 들어, 2024년 1월 LEO Pharma AS는 Timber Pharmaceuticals의 전략적 자산인 TMB-001 및 기타 자산을 인수했다고 발표했는데, TMB-001은 미충족 수요가 높은 여러 중등도에서 중증의 선천성 어루러기 아형에 대한 국소 치료제를 개발하고 있습니다. 을 개발하고 있습니다. 또한, 2023년 2월 화이자는 미국 식품의약국(FDA)으로부터 중등도에서 중증의 아토피피부염(AD)을 앓고 있는 청소년을 대상으로 다른 전신 치료제가 적합하지 않거나 권장되지 않는 경우 아브로시티닙의 사용을 확대하기 위한 추가신약허가신청(sNDA)을 승인받았습니다.
따라서 위의 모든 요인들이 종합적으로 2024-2030년 예측 기간 동안 전체 피부과 의약품 시장을 견인할 것으로 예상됩니다.
그러나 높은 의약품 개발 비용, 피부과 의약품의 부작용, 규제 당국의 까다로운 승인 절차로 인해 피부과 의약품의 시장 성장에 제동이 걸릴 수 있습니다.
북미가 전체 피부과 의약품 시장을 독점할 것으로 예상됩니다.
전 세계 지역 중 북미가 2023년 피부과 의약품 시장을 장악했으며, 2024-2030년 예측 기간 동안에도 마찬가지일 것으로 보입니다. 이는 여드름, 아토피 피부염, 건선, 주사 등 다양한 피부 질환의 유병률이 증가함에 따라 환자들 사이에서 피부과 의약품에 대한 수요가 증가하고 있기 때문입니다. 또한, 일반의약품(OTC)으로서의 피부과 의약품의 증가, 제네릭 의약품에 대한 수요 급증, 피부 관리에 대한 인식 증가, 주요 국내 기업의 존재감, 지역 내 제품 출시 및 승인 증가 등이 북미 피부과 의약품 시장의 성장에 기여하고 있습니다.
이 보고서는 세계 피부과 의약품 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등을 조사 분석하여 전해드립니다.
Dermatological Drugs Market by Drug Class (Anti-Infectives, Corticosteroids, Anti-Acne, Calcineurin Inhibitors, Retinoids, and Others), Indication (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2030 owing to the increasing burden of dermatological disorders such as acne, alopecia areata, psoriasis, atopic dermatitis, rosacea, among others and with the increasing research & development activities in dermatological drugs across the globe
The dermatological drugs market will grow at a CAGR of 10.62% during the forecast period from 2024 to 2030 to reach USD 30,880.13 million by 2030. The dermatological drugs market is observing significant growth due to the growing burden of various dermatological disorders across the globe. Moreover, the rising awareness of skin health among people, their growing expenditure on skincare and personal care, the surging burden of geriatric patients prone to dermatological disorders, and the increasing number of adolescent groups prone to acne and other puberty-related skin disorders will contribute towards driving the market of dermatological drugs in the upcoming years. Therefore, the market for dermatological drugs is estimated to grow at a substantial CAGR during the forecast period from 2024 to 2030.
Dermatological Drugs Market Dynamics:
One of the key aspects driving the dermatological drugs market is the rising burden of numerous skin disorders across the globe. For example, the growing concern about skin problems such as acne, melasma, fine lines, and wrinkles is a significant factor driving the growth of the dermatological drugs market. As the population grows, more people reach adolescence, where they face certain skin issues such as pimples, acne, and redness on the face, among others, as a result of hormonal and bodily changes. Acne causes temporary or permanent scarring, a negative self-image, and anxiety, which leads to the consideration of various dermatological drugs among people.
Moreover, the increasing awareness among the public about their skin health will aid in supporting the market growth of dermatological drugs. Owing to the influence of celebrity culture, social media, beauty pageants, movies, beauty advertisements, and other factors, women's desire for clear, healthy, and attractive-looking skin, all the factors positively impact the dermatological drugs market.
According to the latest study done by the National Organization for Rare Disorders, prevalence of Pachyonychia congenita (PC), a rare keratinizing skin disorder was reported to be between 5,000 and 10,000 in 2021, worldwide. Thus, associated drugs are expected to be in high demand, owing to the increasing number of such dermatological disease cases.
Further, the growing geriatric population is another driver for the dermatological drugs market growth. According to the World Health Organization (WHO) 2021, the world population is aging at a faster phase, and by 2050 there will be 80% of aged people living worldwide. The increasing age makes people more prone to skin problems like wrinkles, saggy skin, blemishes, and rough skin among other issues more gradually than others. Thus, these large number of people opting for anti-aging treatment by dermatological drugs such as Rapamycin and others eventually ensures the increasing overall market share for dermatological drugs.
The increasing strategic activities by the key players, rising product approvals, and launches are increasing the demand for dermatological drugs in the market. For instance, in January 2024, LEO Pharma AS announced acquisitions of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals. It develops a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis - a skin disease with significant unmet need. Also, in February 2023, Pfizer Inc. received the US Food and Drug Administration (FDA) approval for supplemental new drug application (sNDA) to expand the use of abrocitinib, for adolescents with moderate to severe atopic dermatitis (AD) when other systemic drug products are not adequate or advisable.
Therefore, all the factors stated above collectively are expected to drive the overall dermatological drugs market throughout the forecast period from 2024 to 2030.
However, the high cost of drug development, the side effects of dermatological drugs, and the timeline of stringent regulatory approval process may halt the market growth of dermatological drugs.
Dermatological Drugs Market Segment Analysis:
Dermatological Drugs Market by Drug Class (Anti-Infectives, Corticosteroids, Anti-Acne, Calcineurin Inhibitors, Retinoids, and Others), Indication (Alopecia, Herpes, Psoriasis, Rosacea, Atopic Dermatitis, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the indication segment of the dermatological drugs market, the psoriasis category is expected to have a significant revenue share in the year 2023. This is primarily owing to the increasing cases of psoriasis across the globe. Also, the rising launches, strategic investments, and other activities by key players related to the segment will support in driving the market during the forecast period.
According to the National Psoriasis Foundation (2022), about 125 million people were living with psoriasis across the globe. Also, as per the same source, it was stated that 30 percent of people with psoriasis also developed psoriatic arthritis. Additionally, patients with psoriasis incurred annual healthcare costs that are substantially higher than those of the general population. Therefore, from all the above-stated statistics, this category is slated to witness a profitable revenue share in the dermatological drug market and hence promote its overall market growth.
Further, various strategic steps by key players in the market will help in increasing the demand for dermatologicals. For instance, in February 2021, Bristol Myers Squibb Company announced positive results from POETYK PSO-2, the second pivotal Phase III clinical trial evaluating deucravacitinib, a novel, selective tyrosine kinase 2 inhibitor for the treatment of patients with moderate to severe plaque psoriasis. POETYK PSO-2 evaluated deucravacitinib 6 mg once daily and met both co-primary endpoints with significantly more patients achieving Psoriasis Area and Severity Index (PASI 75). Thus, the presence of such psoriasis-treating dermatological drugs in the pipeline may create lucrative growth opportunities for key players in expanding their market and thus in driving the dermatological drugs market during the forecast period.
Thus, owing to all the above-mentioned factors, the demand for psoriasis-treating dermatological drugs upsurges, thereby the category is expected to witness significant growth eventually contributing to the overall growth of the dermatological drugs market during the forecast period from 2024 to 2030.
North America is expected to dominate the overall dermatological drugs market:
Among all the regions, North America is expected to dominate the dermatological drugs market in the year 2023 and is expected to do the same during the forecast period from 2024 to 2030. This can be ascribed to the increasing demand for dermatological drugs in the region owing to its increasing demand among the patients due to the rising prevalence of various dermatological disorders such as acne, atopic dermatitis, psoriasis, rosacea, and others. Further, the increasing number of dermatological drugs as over the counter (OTC), surging demand for generic drugs, the rising awareness about skincare, the presence of key domicile players, rising product launches and approvals in the region, and others are contributing to the growth of the dermatological drugs market in North America.
According to the American Academy of Dermatology Association 2022, about 9,500 people are diagnosed with skin cancer daily in the US and around 3 million non-melanoma skin cancer (NMSC) are estimated to be reported annually. Melanoma is the deadliest form of skin cancer which is growing severely in North America. Various dermatological drugs are used to manage melanoma, ultimately responsible for the surged demand for dermatological drugs.
Furthermore, various domicile players are conducting clinical trials on dermatological drugs, which will create an opportunity for the market to grow in the upcoming years. For instance, In October 2023, Janssen Pharmaceuticals, Inc., a Johnson & Johnson company announced that the recent Phase 3b topline results from Cohort A of the VISIBLE trial, the first prospective, large-scale, randomized-controlled study, focused on evaluating TREMFYA (guselkumab) in patients with moderate to severe plaque psoriasis and scalp psoriasis across all skin tones. At week 16, the trial objectively measured clearance and other treatment outcomes, demonstrating significant efficacy of TREMFYA(R) in achieving these clinical endpoints. This trial underscores the therapeutic potential of guselkumab in a diverse patient population, highlighting its role in the comprehensive management of psoriasis. Therefore, owing to such studies carried out by key players in the region, it may generate future opportunities thereby leading to a notable growth in the dermatological drugs market in North America.
In addition, in October 2023, Ortho Dermatologics received the United States Food and Drug Administration (FDA) approval for IDP-126 gel (CABTREO; clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%, for the topical treatment of acne vulgaris.
Thus, due to the interplay of all the above-mentioned factors, it will lead to an increase in North America dermatological drugs market growth during the forecast period from 2024 to 2030.
Dermatological Drugs Market Key Players:
Some of the key market players operating in the Dermatological Drugs market include Amgen Inc, Bausch Health Companies Inc, Novartis AG, AbbVie Inc, Almirall, S.A, Bristol-Myers Squibb Company, Sanofi, GALDERMA, GSK plc, Pfizer Inc, LEO Pharma AS, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd, Aclaris Therapeutics, Inc, Lupin, and others.
Recent Developmental Activities in the Dermatological Drugs Market:
Key Takeaways from the Dermatological Drugs Market Report Study
Target Audience who can be benefited from this Dermatological Drugs Market Report Study
Frequently Asked Questions for the Dermatological Drugs Market:
Dermatology is a branch of medicine that focuses on the diagnosis, prevention, and treatment of skin diseases, including hair and nail problems. Dermatological drugs are medications used to treat skin diseases. Laser therapy, topical, and systemic medications, photodynamic therapy, radiotherapy, vitiligo surgery, and dermatological surgery are all forms of skin treatment. These dermatological drugs are also used in skincare to keep skin features like radiance and healthiness.
The dermatological drugs market will grow at a CAGR of 10.62% during the forecast period from 2024 to 2030 to reach USD 30,880.13 million by 2030.
The dermatological drugs market is slated to witness prosperity owing to the growing burden of dermatological disorders, rising awareness of skin problems especially among the young group, soaring people's spending power on skincare and personal care, the surging burden of geriatric patients prone to dermatological disorders, surging new drug launches and approvals, presence of key players in the market, and others thus creating an exigency for the dermatological drugs market during the forecast period from 2024 to 2030.
Some of the key market players operating in Dermatological Drugs market include Amgen Inc, Bausch Health Companies Inc, Novartis AG, AbbVie Inc, Almirall, S.A, Bristol-Myers Squibb Company, Sanofi, GALDERMA, GSK plc, Pfizer Inc, LEO Pharma AS, Eli Lilly and Company, Sun Pharmaceutical Industries Ltd, Aclaris Therapeutics, Inc, Lupin, and others.
North America is expected to dominate the overall Dermatological Drugs market during the forecast period from 2024 to 2030. This is due to the increasing demand for dermatological drugs among the patients in the region due to the increasing prevalence of various dermatological disorders such as acne, atopic dermatitis, psoriasis, rosacea, and others. Further, the increasing number of dermatological drugs as over the counter (OTC), the rising awareness about skincare, and the presence of key domicile players in the region are factors supporting the growth of the North America dermatological drugs market.